Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases.
Yamamichi G, Kato T, Yoshimura A, Tani M, Horibe Y, Liu Y, Sassi N, Okuda Y, Oka T, Uemura T, Yamamoto A, Ishizuya YU, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Takao T, Nishimura K, Takada S, Tsujihata M, Nonomura N.
Yamamichi G, et al. Among authors: uemura t.
Anticancer Res. 2025 Feb;45(2):639-650. doi: 10.21873/anticanres.17451.
Anticancer Res. 2025.
PMID: 39890197